Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Cognitive enhancement has become an important target for drug therapies in schizophrenia. Treatment development in this area requires assessment approaches that are sensitive to procognitive effects of antipsychotic and adjunctive treatments. Ideally, new treatments will have translational characteristics for parallel human and animal research. Previous studies of antipsychotic effects on cognition have relied primarily on paper-and-pencil neuropsychological testing. No study has directly compared neurophysiological biomarkers and neuropsychological testing as strategies for assessing cognitive effects of antipsychotic treatment early in the course of schizophrenia. Antipsychotic-naive patients with schizophrenia were tested before treatment with risperidone and again 6 weeks later. Matched healthy participants were tested over a similar time period. Test-retest reliability, effect sizes of within-subject change, and multivariate/univariate analysis of variance were used to compare 3 neurophysiological tests (visually guided saccade, memory-guided saccade, and antisaccade) with neuropsychological tests covering 4 cognitive domains (executive function, attention, memory, and manual motor function). While both measurement approaches showed robust neurocognitive impairments in patients prior to risperidone treatment, oculomotor biomarkers were more sensitive to treatment-related effects on neurocognitive function than traditional neuropsychological measures. Further, unlike the pattern of modest generalized cognitive improvement suggested by neuropsychological measures, the oculomotor findings revealed a mixed pattern of beneficial and adverse treatment-related effects. These findings warrant further investigation regarding the utility of neurophysiological biomarkers for assessing cognitive outcomes of antipsychotic treatment in clinical trials and in early-phase drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey
Brozoski, T. J., Brown, R. M., Rosvold, H. E., & Goldman, P. S. (1979) · Science · doi:10.1126/science.112679 · Cited by 1,500
Cognitive Inflexibility After Prefrontal Serotonin Depletion
Clarke, H. F., Dalley, J. W., Crofts, H. S., Robbins, T. W., & Roberts, A. C. (2004) · Science · doi:10.1126/science.1094987 · Cited by 632
Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
Arnsten, A. F. T., Cai, J. X., Murphy, B. L., & Goldman-Rakic, P. S. (1994) · Psychopharmacology · doi:10.1007/bf02245056 · Cited by 566 · cited 2×
“With regard to the memoryguided saccade effect, which we recently replicated in an independent sample,(52) this measure has been used by the Yale group to investigate drug effects on spatial working memory systems in nonhuman primates.(53) Via reduction of thalamocortical drive, effects on D1 receptor expression, or o…”
BackgroundMethodBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161 · cited 1×
“While the 2-way repeated measures MANOVA for neuropsychological tests indicated that these changes were not statistically significant, the Verbal Fluency increase was consistent with clinical trial data showing a significant increase in Verbal Fluency following treatment with risperidone (Fagerlund, 2004; Harvey et al…”
ResultMurphy, E. R., Dalley, J. W., & Robbins, T. W. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2068-3 · Cited by 145
Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia
Reilly, J. L., Harris, M. S. H., Khine, T. T., Keshavan, M. S., & Sweeney, J. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.031 · Cited by 91
Self-citation
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Self-citationMeta-analysis of cognitive performance in drug-naïve patients with schizophrenia
Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G., & Farde, L. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.034 · Cited by 273
Pharmacological treatment effects on eye movement control
Reilly, J. L., Lencer, R., Bishop, J. R., Keedy, S., & Sweeney, J. A. (2008) · Brain and Cognition · doi:10.1016/j.bandc.2008.08.026 · Cited by 248
Self-citationNeurocognitive allied phenotypes for schizophrenia and bipolar disorder
Hill, S. K., Harris, M. S. H., Herbener, E. S., Pavuluri, M., & Sweeney, J. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn027 · Cited by 123
Self-citationKaratekin, C., Bingham, C., & White, T. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp035 · Cited by 47
Metadata
- Authors
- Hill, S. K., Reilly, J. L., Harris, M. S. H., Khine, T., & Sweeney, J. A.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-04
- Volume
- 34
- Issue
- 3
- Pages
- 494-506
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2137657641
- Cited by
- 28
- References
- 9
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia. https://app.cochat.ai/papers/10.1093/schbul/sbm112
- The paper
- Hill, S. K., Reilly, J. L., Harris, M. S. H., Khine, T., & Sweeney, J. A. (2007). Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbm112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.